MARLBOROUGH, Mass.–(BUSINESS WIRE) August 31, 2018 –Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the New Drug Application (NDA) for dasotraline, a…Original Article
FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
